Parker Waichman LLP

Suprane, Colazal Need New Warnings on Heart, Lung Risks, FDA Staff Says

Some Food & Drug Administration (FDA) advisors are pushing for new warnings on the labels of Suprane and Colazal because of potential risks these drugs may pose when used in children. An FDA safety panel is scheduled to meet tomorrow to discuss the safety of Suprane and Colazal,  as well as other medications used in […]

Some Food & Drug Administration (FDA) advisors are pushing for new warnings on the labels of <"https://www.yourlawyer.com/practice_areas/defective_drugs">Suprane and Colazal because of potential risks these drugs may pose when used in children. An FDA safety panel is scheduled to meet tomorrow to discuss the safety of Suprane and Colazal,  as well as other medications used in children.

Suprane, an anesthetic manufactured by Baxter International, has been associated with instances of cardiac arrest when it has been used in children. According to Baxter’s website, Suprane is indicated as an inhalation agent for induction and/or maintenance of general anesthesia for inpatient  and outpatient surgery.  On December 15, 2006, the FDA approved an expanded indication of Suprane, allowing its use for the maintenance of anesthesia in infants and children, after induction with other agents and tracheal intubation.

According to documents posted on the FDA website, the agency has received three reports of cardiac arrest in children who were administered Suprane.  All of the children did eventually recover with treatment.  The FDA staff said it was possible the cases were associated with Suprane. However they also said each of the patients was being treated with other drugs that may cause cardiac arrest. Despite the uncertainty, the FDA reviewers said Suprane’s label “should be revised to include cardiac arrest.”

The label for Suprane already carries warnings about other cardiac problems including heart attacks, irregular heart beats and unstable blood pressure.

Colazal was approved by the FDA in July 2000 for the treatment of mildly to moderately active ulcerative colitis. At approval, Colazal was the first oral new chemical entity approved in ten years and the first new therapy approved in seven years by the FDA for this indication.   Colazal was one of Salix Pharmaceuticals Ltd.’s biggest selling drugs, but sales were hit hard in December because of the introduction of the introduction of generic competitors.  The FDA staff has recommended that Colazal add new warnings on heart and lung risks to match those now carried by other drugs in the same class.

The FDA periodically reviews the safety of medicines recently approved for pediatric use, as required by the Best Pharmaceuticals for Children Act of 2002. According to the agency, outside experts on the agency’s Pediatric Advisory Committee will consider the recommend label changes on Tuesday.

What Our Clients Say About Us
We have worked with thousands of clients and we appreciate them and their positive reviews. Here are just a few recent client reviews...
5 Star Reviews 150
I am so grateful to Julie Trinidad and Maryann who have been amazing every step of the way. They are quick to respond, kept me updated throughout this process and eased my mind by answering all my questions. Thank you again for all your hard work and support.
Allyson Paige
2 months ago
5 Star Reviews 150
This is my second time using Parker Waichman, needless to say I was pleased the first time. This time I was blessed to have David Aminov. This man works hard! Always updating me on my case which I’ve had open since 2018. I am very pleased, & will be recommending everyone I know to Parker Waichman. Thank you again, I appreciate you all so much, especially Mr. Aminov.
Logan Oliver
4 weeks ago
5 Star Reviews 150
Excellent service, I am very grateful for what they did for my accident case and I thank Ana Palacios for her attention and kindness and I recommend all the staff for your case.
Erasmo Garcia
8 months ago

Why Choose Us to Help You?

We Take Care of Everything
Your situation is stressful enough: Let us take on the deadlines, paperwork, investigation, and litigation. We'll handle every detail so you don't have to worry.
No Recovery = No Legal Fees
We work on a contingency-fee basis, meaning that we only get paid from a portion of your settlement or jury award. If you don't get compensation, you owe us nothing.
Decades of Experience
Your situation is stressful enough: Let us take on the deadlines, paperwork, investigation, and litigation. We'll handle every detail so you don't have to worry.
Respected by Our Peers
Judges, insurance adjusters, and fellow attorneys all speak highly of our skills, and we've earned numerous accolades, including a flawless rating from AVVO.
We Have Many Locations To Serve You
We have the experience and the skilled litigators to win your case. Contact us and speak with a real attorney who can help you.
Long Island – Nassau
Parker Waichman LLP
6 Harbor Park Drive
Port Washington, NY 11050
Long Island – Suffolk
Parker Waichman LLP
201 Old Country Road – Suite 145
Melville, NY 11747
New York
Parker Waichman LLP
59 Maiden Lane, 6th Floor
New York, NY 10038
Queens
Parker Waichman LLP
118-35 Queens Boulevard, Suite 400
Forest Hills, NY 11375
Brooklyn
Parker Waichman LLP
300 Cadman Plaza West
One Pierrepont Plaza, 12th Floor
Brooklyn, NY 11201
New Jersey
Parker Waichman LLP
80 Main Street, Suite 265
West Orange, NJ 07052
Florida
Parker Waichman LLP
27299 Riverview Center Boulevard
Suite 108
Bonita Springs, FL 34134
Nationwide Service
Parker Waichman LLP
59 Maiden Lane, 6th Floor
New York, NY 10038